The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

By C. Currie, C. Poole, E. Gale. Diabetologia, 2009

1,148 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Molecular mechanisms of cancer development in obesity (2011, background): “Accumulating data suggest that patients who are taking insulin or drugs that increase insulin secretion (for example, sulphonylureas) may have higher risks of cancer than patients taking oral insulin-sensitizing agents such as metformin or thiazolidinediones (TZDs”
Diabetes and Cancer (2010, neutral): “However, most of these studies had very few cancer cases among users of sulfonylureas, and therefore power was limited to examine associations with specific cancer sites (91,111).”
Metformin: historical overview (2017, background): “Reduced cancer risk was tentatively indicated in the UKPDS and has subsequently been identified in large database analyses, suggesting that metformin might protect against certain cancers in individuals with type 2 diabetes, notably in the bowel where drug exposure is high, and this has opened a who”